Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Telix and United Imaging Announce Strategic Theranostics Collaboration
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Why Is Regeneron Stock Sinking Monday?
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 Transcript
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
Telix Refinances Convertible Bonds
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
FDA Accepts NDA for TLX101-Px (Pixclara®)
Telix Strengthens Board with Additional Director Appointments
Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook
Why Is Telix Pharma Stock Soaring Tuesday?
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of “Moderate Buy” from Analysts
Telix Appoints David Gill as Non-Executive Director
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
Telix Pharmaceuticals Highlights $1B Revenue Track, Pixclara Resubmission, PSMA Growth at Oppenheimer Conf.
Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx
Investor Education Webinar
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
Telix Pharmaceuticals (TLX) Expected to Announce Quarterly Earnings on Thursday
Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
TLX FINAL DEADLINE ALERT: Hagens Berman Alerts Telix Pharm. (TLX) Investors of Today's Lead Plaintiff Deadline in Securities Class Action
TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX